Combination of a p53-activating CP-31398 and an MDM2 or a FAK inhibitor produces growth suppressive effects in mesothelioma with wild-type p53 genotype

[1]  Xiao-lan Li,et al.  Hippo component YAP promotes focal adhesion and tumour aggressiveness via transcriptionally activating THBS1/FAK signalling in breast cancer , 2018, Journal of experimental & clinical cancer research : CR.

[2]  D. Sterman,et al.  Updates in the diagnosis and treatment of malignant pleural mesothelioma , 2018, Current opinion in pulmonary medicine.

[3]  M. Shingyoji,et al.  Heat shock protein 90 inhibitors augment endogenous wild-type p53 expression but down-regulate the adenovirally-induced expression by inhibiting a proteasome activity , 2018, Oncotarget.

[4]  R. Plummer,et al.  A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Thomas D. Wu,et al.  Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations , 2016, Nature Genetics.

[6]  M. Serrano,et al.  Stabilization of p21 by mTORC1/4E-BP1 predicts clinical outcome of head and neck cancers , 2016, Nature Communications.

[7]  I. Vitale,et al.  Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy , 2015, Molecular & Cellular Oncology.

[8]  M. Meyerson,et al.  Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. , 2015, Cancer research.

[9]  C. Hanemann,et al.  The p53/mouse double minute 2 homolog complex deregulation in merlin‐deficient tumours , 2015, Molecular oncology.

[10]  Andrea I. McClatchey,et al.  Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship , 2014, Science Translational Medicine.

[11]  T. Leto,et al.  Wild-type and mutant p53 differentially regulate NADPH oxidase 4 in TGF-β-mediated migration of human lung and breast epithelial cells , 2014, British Journal of Cancer.

[12]  A. Giordano,et al.  Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma , 2014, Cell cycle.

[13]  M. Donadelli,et al.  Autophagy induced by p53-reactivating molecules protects pancreatic cancer cells from apoptosis , 2013, Apoptosis.

[14]  F. Speleman,et al.  Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. , 2009, Journal of the National Cancer Institute.

[15]  W. El-Deiry,et al.  Structural and Functional Basis for Therapeutic Modulation of p53 Signaling , 2008, Clinical Cancer Research.

[16]  V. Golubovskaya,et al.  p53 regulates FAK expression in human tumor cells , 2008, Molecular carcinogenesis.

[17]  Susan J Fisher,et al.  Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. , 2008, Molecular cell.

[18]  David R Bickers,et al.  CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. , 2007, The Journal of clinical investigation.

[19]  Amie Y Lee,et al.  Update on the molecular biology of malignant mesothelioma , 2007, Cancer.

[20]  R. Stahel,et al.  p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma. , 2006, Neoplasia.

[21]  K. Kito,et al.  Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES‐10 cells) highly expressing vascular endothelial growth factor and its receptor , 2006, Cancer science.

[22]  V. Golubovskaya,et al.  Direct Interaction of the N-terminal Domain of Focal Adhesion Kinase with the N-terminal Transactivation Domain of p53* , 2005, Journal of Biological Chemistry.

[23]  M. Demma,et al.  CP-31398 Restores DNA-binding Activity to Mutant p53 in Vitro but Does Not Affect p53 Homologs p63 and p73* , 2004, Journal of Biological Chemistry.

[24]  W. El-Deiry,et al.  Restoring p53-Dependent Tumor Suppression , 2003, Cancer biology & therapy.

[25]  Gang Li,et al.  The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway. , 2002, Experimental cell research.

[26]  Galina Selivanova,et al.  Characterization of the p53-rescue drug CP-31398 in vitro and in living cells , 2002, Oncogene.

[27]  W. El-Deiry,et al.  The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce Apoptosis , 2002, Cancer biology & therapy.

[28]  B. Foster,et al.  Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.

[29]  M. Shingyoji,et al.  A p53-stabilizing agent, CP-31398, induces p21 expression with increased G2/M phase through the YY1 transcription factor in esophageal carcinoma defective of the p53 pathway. , 2019, American journal of cancer research.